MBX Biosciences (MBX) Competitors $22.46 -0.44 (-1.92%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsTrends MBX vs. MOR, JANX, VRNA, PTGX, AMRX, CPRX, AGIO, GERN, AMPH, and ACADShould you be buying MBX Biosciences stock or one of its competitors? The main competitors of MBX Biosciences include MorphoSys (MOR), Janux Therapeutics (JANX), Verona Pharma (VRNA), Protagonist Therapeutics (PTGX), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), Agios Pharmaceuticals (AGIO), Geron (GERN), Amphastar Pharmaceuticals (AMPH), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical preparations" industry. MBX Biosciences vs. MorphoSys Janux Therapeutics Verona Pharma Protagonist Therapeutics Amneal Pharmaceuticals Catalyst Pharmaceuticals Agios Pharmaceuticals Geron Amphastar Pharmaceuticals ACADIA Pharmaceuticals MBX Biosciences (NYSE:MBX) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, community ranking, profitability, media sentiment and institutional ownership. Does the MarketBeat Community prefer MBX or MOR? MorphoSys received 21 more outperform votes than MBX Biosciences when rated by MarketBeat users. However, 100.00% of users gave MBX Biosciences an outperform vote while only 38.46% of users gave MorphoSys an outperform vote. CompanyUnderperformOutperformMBX BiosciencesOutperform Votes4100.00% Underperform VotesNo VotesMorphoSysOutperform Votes2538.46% Underperform Votes4061.54% Do insiders and institutionals hold more shares of MBX or MOR? 18.4% of MorphoSys shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is MBX or MOR more profitable? MBX Biosciences has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. MBX Biosciences' return on equity of 0.00% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MBX BiosciencesN/A N/A N/A MorphoSys -226.79%-694.31%-22.55% Does the media favor MBX or MOR? In the previous week, MBX Biosciences had 3 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for MBX Biosciences and 0 mentions for MorphoSys. MBX Biosciences' average media sentiment score of 0.15 beat MorphoSys' score of 0.08 indicating that MBX Biosciences is being referred to more favorably in the media. Company Overall Sentiment MBX Biosciences Neutral MorphoSys Neutral Do analysts recommend MBX or MOR? MBX Biosciences currently has a consensus price target of $37.25, suggesting a potential upside of 65.85%. MorphoSys has a consensus price target of $11.78, suggesting a potential downside of 37.87%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe MBX Biosciences is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00MorphoSys 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has stronger earnings & valuation, MBX or MOR? MBX Biosciences has higher earnings, but lower revenue than MorphoSys. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMBX BiosciencesN/AN/AN/AN/AN/AMorphoSys$238.28M11.99-$205.35M-$3.48-5.45 SummaryMBX Biosciences beats MorphoSys on 9 of the 13 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get MBX Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBX vs. The Competition Export to ExcelMetricMBX BiosciencesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$715.44M$7.03B$5.40B$19.27BDividend YieldN/A7.96%5.13%3.53%P/E RatioN/A9.93115.5641.72Price / SalesN/A381.421,484.3414.65Price / CashN/A47.3439.6620.86Price / BookN/A5.324.665.39Net IncomeN/A$153.56M$119.06M$985.39M7 Day Performance5.74%0.11%0.80%-0.71%1 Month Performance-4.67%15.22%5.65%-0.97%1 Year PerformanceN/A41.14%36.76%25.05% MBX Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBXMBX Biosciences2.3994 of 5 stars$22.46-1.9%$37.25+65.9%N/A$715.44MN/A0.0036MORMorphoSys0.1759 of 5 stars$18.96flat$11.78-37.9%N/A$2.86B$238.28M-5.45730News CoverageJANXJanux Therapeutics2.979 of 5 stars$54.39+0.7%$66.44+22.2%+747.2%$2.84B$8.08M-59.7730Upcoming EarningsInsider SellingNews CoverageVRNAVerona Pharma2.0593 of 5 stars$34.98+3.1%$39.33+12.4%+145.0%$2.76B$460,000.00-22.7130Upcoming EarningsPTGXProtagonist Therapeutics3.0629 of 5 stars$46.76+2.0%$52.83+13.0%+209.5%$2.70B$319.12M17.85125Upcoming EarningsNews CoverageAMRXAmneal Pharmaceuticals3.1934 of 5 stars$8.49+0.2%$9.40+10.7%+118.8%$2.63B$2.60B-13.697,700Upcoming EarningsShort Interest ↓CPRXCatalyst Pharmaceuticals4.7788 of 5 stars$21.89+0.4%$29.50+34.8%+73.2%$2.60B$434.48M40.54167Upcoming EarningsAGIOAgios Pharmaceuticals3.9964 of 5 stars$44.87+1.0%$52.33+16.6%+110.7%$2.55B$26.82M-6.90390Analyst ForecastAnalyst RevisionNews CoverageGERNGeron3.9494 of 5 stars$4.11flat$6.94+69.0%+113.0%$2.48B$240,000.00-11.42141Upcoming EarningsAMPHAmphastar Pharmaceuticals4.6516 of 5 stars$50.73+0.4%$63.00+24.2%+11.6%$2.47B$712.89M16.211,761Upcoming EarningsAnalyst DowngradePositive NewsACADACADIA Pharmaceuticals4.518 of 5 stars$14.81+1.5%$25.56+72.6%-35.4%$2.46B$890.53M82.28510Upcoming Earnings Related Companies and Tools Related Companies MorphoSys Competitors Janux Therapeutics Competitors Verona Pharma Competitors Protagonist Therapeutics Competitors Amneal Pharmaceuticals Competitors Catalyst Pharmaceuticals Competitors Agios Pharmaceuticals Competitors Geron Competitors Amphastar Pharmaceuticals Competitors ACADIA Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:MBX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
